• Viral Conjunctivitis Drugs Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Viral Conjunctivitis Drugs Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
New drugs development in the U.S. to propel growth of the viral conjunctivitis market:
According to study published in the journal Ophthalmology in December 2017, approximately
80% of conjunctivitis cases in the U.S. are associated with viral conjunctivitis. According to
study published in Review of Ophthalmology in January 2017, around 15 per 1000 population
in the U.S. suffer from viral conjunctivitis. As per a study in Review of Optometry in 2016, an
estimated 20,000 new cases, 48,000 cases of recurrences, and prevalence of 4,00,000 cases of
herpes simplex keratitis were reported every year in U.S. Considering this facts, U.S. is expected
to dominate the viral conjunctivitis drugs market. Also, increasing investment for development
of new drugs to treat the viral conjunctivitis are further expected to propel the viral
conjunctivitis drugs market growth. For instance, APD-209 is a drug candidate from Adenovir
Pharma AB to treat epidemic keratoconjunctivitis from adenovirus, which has completed the
phase 2 clinical studies in 2016. There is also increased awareness amongst patients about
approaching the ophthalmologist to treat viral conjunctivitis.
However, there is no direct anti-viral treatment available yet for conjunctivitis, which if
available may open new opportunity in viral conjunctivitis drugs market. To treat viral
conjunctivitis often it becomes difficult to clinically differentiate the viral conjunctivitis from the
bacterial conjunctivitis which leads to miss diagnosis. Many physicians at primary care centers
prescribe antibiotic to treat viral conjunctivitis due to miss diagnosis and this chain of events
limits the expansion of viral conjunctivitis drugs market. According to 2017 study in
Ophthalmology, an estimated 83% patients of acute conjunctivitis visited primary care centers
instead of ophthalmologist, which leads to overlap of diagnosis and treatment of viral
conjunctivitis in turn restraining market growth.
Major Key Players: